BZBenjamin J. Zwan

Benjamin J. Zwan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin J. Zwan has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multi-institutional EPID-based 3D dose reconstruction model in a virtual phantom for standardized patient QA, benchmarking and auditing for stereotactic radiosurgery

    by Benjamin Zwan, Emily Searle, Cameron Stanton, Ching-Ling Teng, Seng Boh Lim, Andrew Dipuglia, Richard Popple, Michael Lovelock, Ashley Cullen, Conor K McGarry, et al.

  • Toward real‐time verification for MLC tracking treatments using time‐resolved EPID imaging

    by Benjamin J. Zwan, Vincent Caillet, Jeremy T. Booth, Emma Colvill, Todsaporn Fuangrod, Ricky O'Brien, Adam Briggs, Daryl J. O’connor, Paul J. Keall, Peter B. Greer

    Purpose: In multileaf collimator (MLC) tracking, the MLC positions from the original treatment plan are continuously modified to account for intrafraction tumor motion. As the treatment is adapted in real time, there is additional risk of delivery errors which cannot be detected using traditional pretreatment dose verification. The purpose of this work is to develop a system for real‐time geometric verification of MLC tracking treatments using an electronic portal imaging device (EPID).Methods: MLC tracking was utilized during volumetric modulated arc therapy (VMAT). During these deliveries, treatment beam images were taken at 9.57 frames per second using an EPID and frame grabber computer. MLC positions were extracted from each image frame and used to assess delivery accuracy using three geometric measures: the location, size, and shape of the radiation field. The EPID‐measured field location was compared to the tumor motion measured by implanted electromagnetic markers. The size and shape of the beam were compared to the size and shape from the original treatment plan, respectively. This technique was validated by simulating errors in phantom test deliveries and by comparison between EPID measurements and treatment log files. The method was applied offline to images acquired during the LIGHT Stereotactic Ablative Body Radiotherapy (SABR) clinical trial, where MLC tracking was performed for 17 lung cancer patients. The EPID‐based verification results were subsequently compared to post‐treatment dose reconstruction.Results: Simulated field location errors were detected during phantom validation tests with an uncertainty of 0.28 mm (parallel to MLC motion) and 0.38 mm (perpendicular), expressed as a root‐mean‐square error (RMSError). For simulated field size errors, the RMSError was 0.47 cm2 and field shape changes were detected for random errors with standard deviation ≥ 2.5 mm. For clinical lung SABR deliveries, field location errors of 1.6 mm (parallel MLC motion) and 4.9 mm (perpendicular) were measured (expressed as a full‐width‐half‐maximum). The mean and standard deviation of the errors in field size and shape were 0.0 ± 0.3 cm2 and 0.3 ± 0.1 (expressed as a translation‐invariant normalized RMS). No correlation was observed between geometric errors during each treatment fraction and dosimetric errors in the reconstructed dose to the target volume for this cohort of patients.Conclusion: A system for real‐time delivery verification has been developed for MLC tracking using time‐resolved EPID imaging. The technique has been tested offline in phantom‐based deliveries and clinical patient deliveries and was used to independently verify the geometric accuracy of the MLC during MLC tracking radiotherapy.


  • Commissioning and quality assurance for VMAT delivery systems: An efficient time‐resolved system using real‐time EPID imaging

    by Benjamin J. Zwan, Michael P. Barnes, Jonathan Hindmarsh, Seng B. Lim, Dale M. Lovelock, Todsaporn Fuangrod, Daryl J. O'Connor, Paul J. Keall, Peter B. Greer

    An ideal commissioning and quality assurance (QA) program for Volumetric Modulated Arc Therapy (VMAT) delivery systems should assess the performance of each individual dynamic component as a function of gantry angle. Procedures within such a program should also be time-efficient, independent of the delivery system and be sensitive to all types of errors. The purpose of this work is to develop a system for automated time-resolved commissioning and QA of VMAT control systems which meets these criteria. The procedures developed within this work rely solely on images obtained, using an electronic portal imaging device (EPID) without the presence of a phantom. During the delivery of specially designed VMAT test plans, EPID frames were acquired at 9.5 Hz, using a frame grabber. The set of test plans was developed to individually assess the performance of the dose delivery and multileaf collimator (MLC) control systems under varying levels of delivery complexities. An in-house software tool was developed to automatically extract features from the EPID images and evaluate the following characteristics as a function of gantry angle: dose delivery accuracy, dose rate constancy, beam profile constancy, gantry speed constancy, dynamic MLC positioning accuracy, MLC speed and acceleration constancy, and synchronization between gantry angle, MLC positioning and dose rate. Machine log files were also acquired during each delivery and subsequently compared to information extracted from EPID image frames. The largest difference between measured and planned dose at any gantry angle was 0.8% which correlated with rapid changes in dose rate and gantry speed. For all other test plans, the dose delivered was within 0.25% of the planned dose for all gantry angles. Profile constancy was not found to vary with gantry angle for tests where gantry speed and dose rate were constant, however, for tests with varying dose rate and gantry speed, segments with lower dose rate and higher gantry speed exhibited less profile stability. MLC positional accuracy was not observed to be dependent on the degree of interdigitation. MLC speed was measured for each individual leaf and slower leaf speeds were shown to be compensated for by lower dose rates. The test procedures were found to be sensitive to 1 mm systematic MLC errors, 1 mm random MLC errors, 0.4 mm MLC gap errors and synchronization errors between the MLC, dose rate and gantry angle controls systems of 1°. In general, parameters measured by both EPID and log files agreed with the plan, however, a greater average departure from the plan was evidenced by the EPID measurements. QA test plans and analysis methods have been developed to assess the performance of each dynamic component of VMAT deliveries individually and as a function of gantry angle. This methodology relies solely on time-resolved EPID imaging without the presence of a phantom and has been shown to be sensitive to a range of delivery errors. The procedures developed in this work are both comprehensive and time-efficient and can be used for streamlined commissioning and QA of VMAT delivery systems.


  • A method for evaluating treatment quality using in vivo EPID dosimetry and statistical process control in radiation therapy

    by Todsaporn Fuangrod, Peter B. Greer, John Simpson, Benjamin J. Zwan, Richard H. Middleton

    Purpose: Due to increasing complexity, modern radiotherapy techniques require comprehensive quality assurance (QA) programmes, that to date generally focus on the pre-treatment stage. The purpose of this paper is to provide a method for an individual patient treatment QA evaluation and identification of a “quality gap” for continuous quality improvement. Design/methodology/approach: A statistical process control (SPC) was applied to evaluate treatment delivery using in vivo electronic portal imaging device (EPID) dosimetry. A moving range control chart was constructed to monitor the individual patient treatment performance based on a control limit generated from initial data of 90 intensity-modulated radiotherapy (IMRT) and ten volumetric-modulated arc therapy (VMAT) patient deliveries. A process capability index was used to evaluate the continuing treatment quality based on three quality classes: treatment type-specific, treatment linac-specific, and body site-specific. Findings: The determined control limits were 62.5 and 70.0 per cent of the χ pass-rate for IMRT and VMAT deliveries, respectively. In total, 14 patients were selected for a pilot study the results of which showed that about 1 per cent of all treatments contained errors relating to unexpected anatomical changes between treatment fractions. Both rectum and pelvis cancer treatments demonstrated process capability indices were less than 1, indicating the potential for quality improvement and hence may benefit from further assessment. Research limitations/implications: The study relied on the application of in vivo EPID dosimetry for patients treated at the specific centre. Sampling patients for generating the control limits were limited to 100 patients. Whilst the quantitative results are specific to the clinical techniques and equipment used, the described method is generally applicable to IMRT and VMAT treatment QA. Whilst more work is required to determine the level of clinical significance, the authors have demonstrated the capability of the method for both treatment specific QA and continuing quality improvement. Practical implications: The proposed method is a valuable tool for assessing the accuracy of treatment delivery whilst also improving treatment quality and patient safety. Originality/value: Assessing in vivo EPID dosimetry with SPC can be used to improve the quality of radiation treatment for cancer patients.


  • Open Access

    The dosimetric impact of control point spacing for sliding gap MLC fields

    by Benjamin J. Zwan, Jonathan Hindmarsh, Erin Seymour, Kankean Kandasamy, Kirbie Sloan, Rajesakar David, Christopher Lee


  • Open Access

    An EPID‐based system for gantry‐resolved MLC quality assurance for VMAT

    by Benjamin J. Zwan, Michael P. Barnes, Todsaporn Fuangrod, Cameron J. Stanton, Daryl J. O'Connor, Paul J. Keall, Peter B. Greer

    Multileaf collimator (MLC) positions should be precisely and independently measured as a function of gantry angle as part of a comprehensive quality assurance (QA) program for volumetric‐modulated arc therapy (VMAT). It is also ideal that such a QA program has the ability to relate MLC positional accuracy to patient‐specific dosimetry in order to determine the clinical significance of any detected MLC errors. In this work we propose a method to verify individual MLC trajectories during VMAT deliveries for use as a routine linear accelerator QA tool. We also extend this method to reconstruct the 3D patient dose in the treatment planning system based on the measured MLC trajectories and the original DICOM plan file. The method relies on extracting MLC positions from EPID images acquired at 8.41 fps during clinical VMAT deliveries. A gantry angle is automatically tagged to each image in order to obtain the MLC trajectories as a function of gantry angle. This analysis was performed for six clinical VMAT plans acquired at monthly intervals for three months. The measured trajectories for each delivery were compared to the MLC positions from the DICOM plan file. The maximum mean error detected was 0.07 mm and a maximum root‐mean‐square error was 0.8 mm for any leaf of any delivery. The sensitivity of this system was characterized by introducing random and systematic MLC errors into the test plans. It was demonstrated that the system is capable of detecting random and systematic errors on the range of 1–2 mm and single leaf calibration errors of 0.5 mm. The methodology developed in the work has potential to be used for efficient routine linear accelerator MLC QA and pretreatment patient‐specific QA and has the ability to relate measured MLC positional errors to 3D dosimetric errors within a patient volume.PACS number(s): 87.55.Qr


  • Open Access

    Investigation of a real-time EPID-based patient dose monitoring safety system using site-specific control limits

    by Todsaporn Fuangrod, Peter B. Greer, Henry C. Woodruff, John Simpson, Shashank Bhatia, Benjamin Zwan, Timothy A. Vanbeek, Boyd M.C. McCurdy, Richard H. Middleton

    The aim of this study is to investigate the performance and limitations of a real-time transit electronic portal imaging device (EPID) dosimetry system for error detection during dynamic intensity modulated radiation therapy (IMRT) treatment delivery. Sites studied are prostate, head and neck (HN), and rectal cancer treatments. The system compares measured cumulative transit EPID image frames with predicted cumulative image frames in real-time during treatment using a χ comparison with 4 %, 4 mm criteria. The treatment site-specific thresholds (prostate, HN and rectum IMRT) were determined using initial data collected from 137 patients (274 measured treatment fractions) and a statistical process control methodology. These thresholds were then applied to data from 15 selected patients including 5 prostate, 5 HN, and 5 rectum IMRT treatments for system evaluation and classification of error sources. Clinical demonstration of real-time transit EPID dosimetry in IMRT was presented. For error simulation, the system could detect gross errors (i.e. wrong patient, wrong plan, wrong gantry angle) immediately after EPID stabilisation; 2 seconds after the start of treatment. The average rate of error detection was 7.0 % (prostate = 5.6 %, HN= 8.7 % and rectum = 6.7 %). The detected errors were classified as either clinical in origin (e.g. patient anatomical changes), or non-clinical in origin (e.g. detection system errors). Classified errors were 3.2 % clinical and 3.9 % non-clinical. An EPID-based real-time error detection method for treatment verification during dynamic IMRT has been developed and tested for its performance and limitations. The system is able to detect gross errors in real-time, however improvement in system robustness is required to reduce the non-clinical sources of error detection.